Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Young Patients With Recurrent Sarcoma
This study is currently recruiting participants.
Study NCT00047372 Information provided by National Cancer Institute (NCI)
First Received: October 3, 2002 Last Updated: May 28, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sarcoma
Additional conditions recognized in this trial
Neuroectodermal Tumors, Primitive, Peripheral
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Interventions listed in this trial
filgrastim
therapeutic allogeneic lymphocytes
cyclophosphamide
cyclosporine
doxorubicin hydrochloride
etoposide
fludarabine phosphate
melphalan
prednisone
sirolimus
tacrolimus
vincristine sulfate
Additional drug interventions recognized in this trial
Cyclosporins
Doxorubicin
Fludarabine
Fludarabine monophosphate
Vidarabine
Vincristine
More general drug interventions related to this trial
Alkylating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Anti-Inflammatory Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Antiviral Agents
Dermatologic Agents
Enzyme Inhibitors
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
